Alkaline protease and application thereof in pearl enzymolysis
By developing and developing modified alkaline proteases and their mutants, the extraction rate and small molecule peptide content of the globin peptide are improved, and the problems of low efficiency and high cost of globinase in the prior art are solved, thus achieving efficient and economical pearls Protein peptide preparation, suitable for the industrial production of cosmetics.
Patent Information
- Application Number
- CN202411246970.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-06
- Publication Date
- 2024-11-26
AI Technical Summary
In the prior art, the enzymatic elutation efficiency of pearl protein is low, high cost, and the extraction effect is not significant, so it is not suitable for large-scale production applications.
A basic protease and its mutant were developed. By modifying the amino acid sequence, catalytic activity and substrate tolerance were improved, and used for the enzymatic process of pearls, which increased the extraction rate of pearl protein peptides and the content of small molecule peptides. .
The extraction rate of the glabin peptide is significantly improved and the production cost is reduced. The obtained glabin peptide has a high content of small and medium-sized polypeptides, which is easy to be absorbed by the skin, and has good permeability, whitening and antioxidant effects.
Smart Images

Figure BDA0005031056580000061 
Figure BDA0005031056580000071 
Figure BDA0005031056580000081
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of industrial enzymes and their application, in particular to alkaline protease and its application in pearl enzymolysis. Background Art
[0002] Pearl is an ancient organic gemstone, mainly produced in pearl oysters and mother-of-pearl oysters. Pearls have always been regarded as precious treasures. They can not only be used as precious ornaments for women, but also as precious beauty products and medicinal materials. Many medical books, such as "Compendium of Materia Medica", record that "pearls are salty, sweet, cold and non-toxic, calming the heart and eyes; pearls applied on the face can make people moisturized and have good color. Applying on hands and feet can remove skin ulcers; remove phlegm, remove facial spots, stop diarrhea; remove children's fright and fever, calm the soul; stop spermatorrhea, white turbidity, detoxify acne and treat toxins, and make the skin shiny and white." Traditional Chinese medicine believes that pearls belong to the heart and liver meridians, and have the effects of moisturizing the skin, promoting muscle growth and delaying skin aging. Modern pharmacological studies have shown that pearls can promote the body's metabolism, increase the vitality of epidermal cells, and delay cell aging. They can maintain moisture on the skin surface through hydration, inhibit tyrosinase activity and the production of melanin, and have pharmacological effects such as removing spots, whitening, detoxifying and promoting muscle growth. Therefore, skin care products containing pearl ingredients are becoming more and more popular among consumers.
[0003] Pearl protein is the main component of pearls that has whitening and antioxidant effects. The main protein in the pearl layer is shell keratin, which has a complex structure and is difficult to dissolve in water and cannot be used directly. Therefore, it is very necessary to carry out deep processing of pearls to achieve high-value utilization of pearl protein. At present, the extraction methods of pearl protein are divided into two categories, including conventional extraction methods and enzymatic extraction methods. Among them, conventional extraction methods include heating and boiling, low-temperature cold soaking, ultrasound-assisted extraction, microwave extraction, acid hydrolysis, etc. However, according to existing research, although the conventional water extraction method is simple to operate, the extraction rate is low, the highest is only 49.7%, and the extracted substances are mostly macromolecular substances that are difficult to be absorbed by the human body. Although the acid hydrolysis method can increase the extraction rate to about 54% to a certain extent, this extraction method has a violent reaction, complex separation and purification, and the use of strong acid leads to the destruction of the polypeptide structure, which inactivates the effective ingredients. Therefore, there are also great application limitations. In order to break through the technical bottlenecks and constraints of traditional extraction methods, there are also reports in the prior art that use enzymes to extract pearl protein. In the existing enzymatic process, the enzymatic hydrolysis of pearls is mostly performed by one or more proteases such as papain, bromelain, and trypsin, but these existing methods all have defects. For example, Chinese patent CN110547458A proposes to use papain, bromelain, trypsin and other proteases in combination, but the extraction rate is only 45%, and the cost of multiple enzymes reacting together is high. Chinese patent CN106265748A uses papain and bromelain to perform secondary enzymatic hydrolysis on pearl powder, and the demand for enzymes is large, thereby increasing the cost of enzymatic hydrolysis. It can be seen that the enzymatic hydrolysis efficiency of pearls in the existing technology is low, the cost is high, and the enzymatic hydrolysis effect is not significant, which is not suitable for large-scale production applications.
[0004] In addition, proteases produced using natural strains have other limitations, including low enzyme activity, slow catalytic reaction rate, and low product yield, which are not conducive to large-scale production applications.
[0005] Therefore, it is very important to develop a more efficient protease for the extraction and preparation of effective active substances in pearls. Summary of the invention
[0006] The present invention aims to solve at least one of the above-mentioned technical problems existing in the prior art. To this end, the purpose of the present invention is to provide an alkaline protease and its use in pearl enzymatic hydrolysis. The present invention provides an alkaline protease (BG1), and further develops an alkaline protease mutant with improved catalytic activity and substrate tolerance on the basis thereof. The alkaline protease and its mutant in the present invention effectively improve the extraction rate of active ingredients (pearl protein peptides) in pearls, and increase the effective content of small molecule peptides therein, thereby effectively improving the relevant effects of pearl protein peptides, and having extremely high economic benefits in industrial production.
[0007] The first aspect of the present invention provides an alkaline protease or a mutant thereof, wherein the alkaline protease comprises an amino acid sequence as shown in SEQ ID NO:1.
[0008] In some embodiments of the present invention, the alkaline protease mutant has an amino acid sequence that has at least 95% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, and the alkaline protease mutant retains protein hydrolysis catalytic activity.
[0009] In some embodiments of the present invention, the alkaline protease mutant has an amino acid sequence that has at least 97% sequence identity with the amino acid sequence shown in SEQ ID NO:1.
[0010] In some embodiments of the present invention, the alkaline protease mutant has an amino acid sequence that has at least 98% or 99% sequence identity with the amino acid sequence shown in SEQ ID NO:1.
[0011] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by replacing, adding or deleting at least one amino acid of the alkaline protease.
[0012] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by replacing, adding or deleting 1 to 8 amino acids of the alkaline protease.
[0013] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by replacing 1 to 8 amino acids in the alkaline protease.
[0014] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by replacing one amino acid in the alkaline protease.
[0015] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by amino acid substitution at at least one amino acid residue among 47S, 57V, 115Q, 136I, 182S, 239L, 262T or 244S of the alkaline protease.
[0016] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by amino acid substitution at 1-2 amino acid residues in 47S, 57V, 115Q, 136I, 182S, 239L, 262T or 244S of the alkaline protease.
[0017] In some embodiments of the present invention, the alkaline protease mutant is an alkaline protease mutant obtained by amino acid substitution at any one of the amino acid residues 47S, 57V, 115Q, 136I, 182S, 239L, 262T or 244S.
[0018] In some embodiments of the present invention, S at position 47 mutates to L, V at position 57 mutates to I, Q at position 115 mutates to L, I at position 136 mutates to L, S at position 182 mutates to A, L at position 239 mutates to M, T at position 262 mutates to A, and S at position 244 mutates to A.
[0019] In some embodiments of the present invention, the alkaline protease mutant comprises an amino acid sequence as shown in SEQ ID NO: 3, 5, 7, 9 or 11.
[0020] In some embodiments of the present invention, the alkaline protease or its mutant is further modified, and the modification includes but is not limited to: glycosylation, phosphorylation, acetylation, methylation, ubiquitination or lipidation; or introduction of non-natural amino acids (such as α-aminoketo acid or β-aminoketo acid).
[0021] The second aspect of the present invention provides a biological product, comprising:
[0022] (1) A nucleic acid molecule encoding the alkaline protease or a mutant thereof according to the above aspects;
[0023] (2) an expression vector containing the nucleic acid molecule described in (1);
[0024] (3) A transformant containing the nucleic acid molecule described in (1);
[0025] (4) a transformant containing the expression vector described in (2);
[0026] In some embodiments of the present invention, the nucleic acid molecule includes a nucleic acid molecule as shown in SEQ ID NO: 2, 4, 6, 8, 10 or 12.
[0027] In the present invention, the term "expressor" refers to a vector or expression system used to integrate or insert a foreign gene of interest.
[0028] In some embodiments of the present invention, the expression vector includes virus, plasmid and bacteriophage.
[0029] In the present invention, the term "transformant" refers to a recipient cell that has acquired a new genetic marker after incorporation or introduction of a foreign gene.
[0030] In some embodiments of the present invention, the transformants include bacteria, fungi, and animal and plant cells.
[0031] In some embodiments of the invention, the transformants do not involve animal or plant reproductive materials.
[0032] In some embodiments of the present invention, the construction of the expression vector and the transformant can be achieved based on any conventional technical means in the art.
[0033] The third aspect of the present invention provides the use of the alkaline protease or its mutant, or biological product described in the above aspects in enzyme engineering.
[0034] In some embodiments of the invention, the enzyme engineering comprises enzymatic hydrolysis of pearl protein peptides.
[0035] The fourth aspect of the present invention provides a method for preparing pearl protein peptide, comprising the following steps: adding alkaline protease to a solution containing pearl powder, and performing enzymolysis at 40-65°C for 2-10 hours to obtain the pearl protein peptide.
[0036] In some embodiments of the present invention, the alkaline protease includes the alkaline protease or a mutant thereof described in the above aspects.
[0037] In some embodiments of the present invention, the enzymatic hydrolysis temperature is 50-60°C.
[0038] In some embodiments of the present invention, the enzymatic hydrolysis time is 4-8 hours.
[0039] In some embodiments of the present invention, the mass ratio of the pearl powder to the protease is 1:0.001-0.04.
[0040] In some embodiments of the present invention, the mass ratio of the pearl powder to the protease is 1:0.01-0.03.
[0041] In some embodiments of the present invention, the material-liquid ratio of the pearl powder to the solvent is 1:5-10.
[0042] In some embodiments of the present invention, the solvent includes but is not limited to: water, PBS buffer, phosphate buffer and other solvents having a buffering function.
[0043] In some embodiments of the invention, no pH adjustment is performed in the method.
[0044] In some embodiments of the present invention, the method further comprises: purifying and / or enriching the enzymatic hydrolysis product after enzymatic hydrolysis.
[0045] In some embodiments of the present invention, the purification and / or enrichment comprises centrifuging, filtering and / or evaporating and concentrating the enzymatic hydrolysis product.
[0046] In some embodiments of the invention, the precipitate is removed after centrifugation.
[0047] In some embodiments of the invention, multiple filtrations are performed.
[0048] In some embodiments of the present invention, the filtering times are 2-5 times; the filtering times are 2 times.
[0049] In some embodiments of the present invention, the evaporative concentration comprises rotary evaporation.
[0050] In some embodiments of the present invention, the rotary evaporation temperature is 50-70°C; in some embodiments of the present invention, the rotary evaporation temperature is 60-70°C.
[0051] In some embodiments of the present invention, the method further comprises performing an enzyme inactivation treatment after the enzymatic hydrolysis.
[0052] In some embodiments of the present invention, the enzyme inactivation treatment comprises at least one of increasing the temperature, adding an enzyme inhibitor, increasing the pressure or applying a voltage.
[0053] In some embodiments of the present invention, the enzyme inactivation treatment adopts a temperature-raising enzyme inactivation method, the temperature after the heating is 80-100° C., and the duration is 10-30 minutes.
[0054] In some embodiments of the present invention, the temperature after heating is 90-15° C. and the duration is 15-25 min.
[0055] In some embodiments of the present invention, the particle size of the pearl powder is less than or equal to the 80-mesh sieve aperture.
[0056] In some embodiments of the present invention, the 80-mesh sieve has a pore size of about 0.18 mm.
[0057] In the present invention, the term "about" refers to a numerical range after a numerical value is increased or decreased by 5%. In some embodiments of the present invention, it refers to a numerical range after a numerical value is increased or decreased by 2%.
[0058] In some embodiments of the present invention, the method further comprises drying the product; in some embodiments of the present invention, the drying comprises freeze drying.
[0059] The fifth aspect of the present invention provides a pearl protein peptide prepared by the preparation method described in the above aspects, wherein the content of small molecule peptides in the pearl protein peptide is greater than or equal to 60%.
[0060] In some embodiments of the present invention, the content of small molecule peptides in the pearl protein peptide is greater than or equal to 80%.
[0061] In some embodiments of the present invention, the content of small molecule peptides in the pearl protein peptide is greater than or equal to 90%.
[0062] In some embodiments of the present invention, the small molecule peptide is a peptide of less than or equal to 13 kDa.
[0063] In some embodiments of the present invention, the small molecule peptide is a peptide of 0.1-13 kDa.
[0064] In some embodiments of the present invention, the pearl protein peptide has significantly improved tyrosinase inhibition, antioxidant properties and moisturizing properties compared to pearl protein peptides prepared by other methods.
[0065] In some embodiments of the present invention, the pearl protein peptide has at least 0.4%-25.6% improvement in tyrosinase inhibition effect compared to pearl protein peptides prepared by other methods.
[0066] In some embodiments of the present invention, the pearl protein peptide has an antioxidant activity improved by at least 11.2%-93.1% compared to pearl protein peptides prepared by other methods.
[0067] In some embodiments of the present invention, the pearl protein peptide has at least 3%-19.4% improved moisturizing performance compared to pearl protein peptides prepared by other methods.
[0068] The sixth aspect of the present invention provides a daily necessity, which contains the pearl protein peptide described in the above aspect.
[0069] In some embodiments of the present invention, the daily necessities further contain other active functional ingredients.
[0070] In some embodiments of the present invention, the daily necessities further contain auxiliary materials.
[0071] In some embodiments of the present invention, the auxiliary materials include but are not limited to emulsifiers, flavors, pigments, preservatives, antioxidants, etc.
[0072] The seventh aspect of the present invention provides the use of the pearl protein peptide described in the above aspects in the preparation of medicines or cosmetics.
[0073] In some embodiments of the present invention, the medicine or cosmetic has at least one of the following functions:
[0074] (1) Antioxidant or anti-aging;
[0075] (2) Whitening and darkening;
[0076] (3) Store water and keep moisturized.
[0077] In some embodiments of the present invention, the medicine or cosmetic has the above functions simultaneously.
[0078] In some embodiments of the present invention, the medicine or cosmetic further contains other active functional ingredients.
[0079] In some embodiments of the present invention, the medicine or cosmetic further contains excipients.
[0080] The beneficial effects of the present invention are:
[0081] (1) The alkaline protease and its mutants in the present invention have high hydrolysis catalytic activity, which greatly reduces the amount of enzyme used in the enzymatic hydrolysis process, and also increases the extraction rate of pearl protein peptides by more than 50%, reducing the production cost by more than 55%. Moreover, it can fully hydrolyze pearl protein, and the obtained pearl protein peptides contain smaller small molecular polypeptide substances (0.1-13kDa) than other enzymatic methods (13kDa-65kDa), and the content exceeds 30% of other enzymatic methods, making the pearl protein obtained by the alkaline protease method more easily absorbed by the skin and having good permeability.
[0082] (2) The enzymatic hydrolysis method of the present invention can use only deionized water as the enzymatic hydrolysis solvent, which has less ion interference and does not require further adjustment of the solvent pH. The enzymatic hydrolysis conditions are simple and mild, the method process is simple, there is no problem of organic solvent residue, it is environmentally friendly, and is very suitable for industrial large-scale production.
[0083] (3) The method of the present invention uses alkaline protease to hydrolyze pearl powder for the first time. The pearl protein peptide obtained by the method is used as a cosmetic raw material to prepare a compound solution, and the whitening effect is improved by 0.4%-25.6%, the antioxidant activity is improved by 11.2%-93.1%, and the moisturizing ability is improved by 3%-19.4%. It can be seen that the alkaline protease selected by the present invention has achieved a better enzymatic hydrolysis effect. The product can be widely used in the preparation of cosmetics, further promoting the efficient application of pearl powder. BRIEF DESCRIPTION OF THE DRAWINGS
[0084] Figure 1 is the chromatogram of the blank solution.
[0085] Figure 2 The chromatogram is that of the reference product.
[0086] Figure 3 is the chromatogram of the test solution. DETAILED DESCRIPTION
[0087] The present invention is further described in detail below by specific examples. Unless otherwise specified, the raw materials, reagents or devices used in the examples and comparative examples can be obtained from conventional commercial sources or can be obtained by prior art methods. Unless otherwise specified, the experiments or test methods are conventional methods in the art.
[0088] In the following examples, the pearl powder used can be commercially available pearl powder or pearl powder obtained by any technical means in the art. In the following examples, commercially available pearl powder is used as an example to demonstrate the relevant effects, but it should be understood that the embodiments of the present invention are not limited by the source of pearl powder.
[0089] Example 1
[0090] In this embodiment, an alkaline protease and a mutant thereof are provided.
[0091] In this example, an alkaline protease (hereinafter named BG1) was developed, and its amino acid sequence is shown in SEQ ID NO:1.
[0092] The corresponding nucleotide sequence is shown in SEQ ID NO:2.
[0093] Using the alkaline protease shown in SEQ ID NO: 1 as the parent, the directed evolution technology was used to transform the activity of the alkaline protease to obtain mutants. The information of some mutants is shown in Table 1.
[0094] Table 1 Alkaline protease mutant information
[0095] Mutant name mutation Amino acid sequence number Nucleotide sequence number The catalytic activity of the parent is increased by multiple times BG1-Q115L Q115L SEQ ID NO:3 SEQ ID NO:4 1.02 BG1-I136L I136L SEQ ID NO:5 SEQ ID NO:6 1.01 BG1-S182A S182A SEQ ID NO:7 SEQ ID NO:8 1.12 BG1-L239M L239M SEQ ID NO:9 SEQ ID NO:10 1.03 BG1-T262A T262A SEQ ID NO:11 SEQ ID NO:12 1.05
[0096] The mutations in Table 1 are represented in the form of: single-letter abbreviation of the amino acid before mutation - mutation position in the parent (from the N-terminus to the C-terminus) - single-letter abbreviation of the amino acid after mutation.
[0097] The specific method for obtaining the mutant is as follows:
[0098] (1) Construct a recombinant plasmid vector containing SEQ ID NO: 2 according to conventional techniques in the art (any commercially available plasmid can be used as the vector).
[0099] (2) Design site-directed mutagenesis primers, use the recombinant plasmid vector containing SEQ ID NO: 2 obtained in step (1) as a template, perform overlap extension PCR, and obtain a mutant plasmid vector.
[0100] Among them, the site-directed mutagenesis primers include primers that mutate the 47th S to L, the 57th V to I, the 115th Q to L, the 136th I to L, the 182nd S to A, the 239th L to M, the 262nd T to A, and the 244th S to A in the BG1 amino acid sequence.
[0101] The site-directed mutagenesis primers for each mutation site are shown in Table 2.
[0102] Table 2 Site-directed mutagenesis primers for each mutation site
[0103] Primer name Primer sequence (5'-3') S47L-F GTGGGCTTTAAAAGCCTGGTGAAAACCGCG(SEQ ID NO:13) S47L-R CGCGGTTTTCACCAGGCTTTTAAAGCCCAC(SEQ ID NO:14) V57I-F GCGGCGGTGAAAAAAGATATTATTAAAGAA(SEQ ID NO:15) V57I-R TTCTTTAATAATATCTTTTTTTCACCGCCGC(SEQ ID NO:16) Q115L-F CCGTATGGCATTCCGCTGATTAAAGCGGATAAA(SEQ ID NO:17) Q115L-R TTTATCCGCTTTAATCAGCGGAATGCCATACGG(SEQ ID NO:18) I136L-F GTGAAAGTGGGCGTGCTGGATACCGGCATT(SEQ ID NO:19) I136L-R AATGCCGGTATCCAGCACGCCCACTTTCAC(SEQ ID NO:20) S182A-F GCGGCGCTGGATAACGCGATTGGCGTGCTG(SEQ ID NO:21) S182A-R CAGCACGCCAATCGCGTTATCCAGCGCCGC(SEQ ID NO:22) L239M-F ACCAGCGGCAGCACCGCGATGAAACAGGCGGTGGATAAAG(SEQ ID NO:23) L239M-R CTTTATCCACCGCCTGTTTCATCGCGGTGCTGCCGCTGGT(SEQ ID NO:24) T262A-F GCGGGCAACAGCGGCGCGAGCGGCAGCAGC(SEQ ID NO:25) T262A-R GCTGCTGCCGCTCGCGCCGCTGTTGCCCGC(SEQ ID NO:26)
[0104] (3) The mutant plasmid vector is transfected into cells (host bacteria) and then screened to obtain mutant expression strains with positive clones. After sequencing verification, the alkaline protease mutants are extracted from the strains.
[0105] In this example, 8 alkaline protease mutants containing the above mutations were obtained, wherein the nucleotide sequences of BG1-S47L and V57I are shown in SEQ ID NOs: 27 and 28.
[0106] Example 2
[0107] This embodiment provides a method for preparing pearl protein peptide, comprising the following steps:
[0108] (1) Pearl powder and purified water are mixed to obtain a pearl powder water suspension, wherein the ratio of pearl powder to purified water is 1 g:10 mL. Subsequently, protease is added to the pearl powder water suspension at a ratio of 0.02 g of protease per 1 g of pearl powder, and enzymolysis is performed at 55° C. for 4 hours to obtain an enzymolysis solution.
[0109] (2) The temperature of the enzymatic hydrolyzate obtained in step (1) was raised to 95° C., and the enzyme was inactivated for 20 min.
[0110] (3) The enzymatic hydrolysate after the enzyme inactivation in step (2) is cooled to room temperature, and then centrifuged at 8000 rpm in a high-speed centrifuge to remove the precipitate and obtain the enzymatic hydrolysate supernatant.
[0111] (4) Using a 90 mm glass funnel and double-layer medium-speed filter paper, filter the supernatant of the enzymatic hydrolyzate obtained in step (3) twice to remove impurities.
[0112] (5) The enzymatic hydrolysate filtered in step (4) is concentrated by rotary evaporation at 65° C., wherein the volume of the enzymatic hydrolysate after concentration is 1 / 10 of that before concentration.
[0113] (6) freeze-drying the concentrated enzymatic hydrolysate obtained in step (5) using a freeze dryer to obtain pearl protein peptide dry powder. The freeze-drying treatment conditions at least meet at least one of the following: the vacuum degree of the freeze-drying treatment is 1 Pa, the temperature is -80°C, and the time is 120 hours.
[0114] In this example, in order to compare the pearl protein peptide yields and preparation costs of different proteases, the inventors used 7 different proteases including alkaline protease (BG1) and acidic protease, neutral protease, trypsin, bromelain, papain, and flavor protease in this application for enzymatic hydrolysis, and detected their respective pearl protein peptide yields.
[0115] Among them, the method for determining the content of pearl protein peptide is as follows:
[0116] (1) Weigh 0.2 g of the pearl protein peptide freeze-dried powder obtained by enzymatic hydrolysis with different proteases (i.e., the product of step (6) above) and transfer it into a nitrogen determination bottle. Add 0.1 g of copper sulfate, 1 g of potassium sulfate, and 5 mL of sulfuric acid. After shaking, place a small funnel at the mouth of the bottle and place the nitrogen determination bottle at a 45-degree angle on an asbestos net with small holes.
[0117] (2) Heat slowly until the contents are completely carbonized and the foam stops completely. Then increase the heat and keep the liquid in the bottle boiling slightly. Heat for another 0.5 h until the liquid becomes clear and blue-green.
[0118] (3) Remove the tube and let it stand at room temperature. Slowly add 20 mL of purified water. After cooling, transfer it to a 100 mL volumetric flask. Rinse the nitrogen determination bottle with a small amount of water and add the washing liquid to the volumetric flask. Add water to the mark and mix well for later use.
[0119] (4) Pipette 2 mL of the mixed solution in step (3) as the sample solution (with an equal amount of blank digestion solution as the control) into a 10 mL volumetric flask, add 2 drops of p-nitrophenol indicator solution, shake well, add sodium hydroxide solution dropwise to neutralize until it turns yellow, then add acetic acid solution dropwise until the solution no longer changes color, dilute with water to the scale line, and shake well.
[0120] (5) Drawing of standard curve: Pipette 0.00mL, 0.05mL, 0.10mL, 0.20mL, 0.40mL, 0.60mL, 0.80mL and 1.00mL of nitrogen and ammonia standard working solution respectively and place them in 10mL colorimetric tubes. Add 4.0mL of sodium acetate-acetic acid buffer solution and 4.0mL of color developer, dilute to the scale with water and mix well. Heat in a 100℃ water bath for 15min. Take out and cool to room temperature with water, transfer to a 10mm×10mm quartz glass cuvette, use the zero tube as a reference, measure the absorbance at a wavelength of 400nm, draw a standard curve based on the absorbance values at each point of the standard, and calculate the linear regression equation.
[0121] (6) Sample determination: Pipette 1.0 mL of the sample solution treated in step (4) and an equal amount of the reagent blank digestion solution into a 10 mL colorimetric tube. Add 4.0 mL of sodium acetate-acetic acid buffer solution and 4.0 mL of color developer, dilute to the mark with water, and mix well. Heat in a 100°C water bath for 15 min. Take out and cool to room temperature with water, transfer to a 10 mm × 10 mm quartz glass cuvette, use the reagent blank solution as a reference, measure the absorbance at a wavelength of 400 nm, and substitute the sample absorbance into the linear regression equation to calculate the content.
[0122] The specific calculation formula is:
[0123]
[0124] Where:
[0125] X-protein content in the sample, in grams per hundred grams (g / 100g); C-nitrogen content in the sample test solution, in micrograms (μg); C0-nitrogen content in the sample blank test solution, in micrograms (μg); V1-volume of sample digestion solution, in milliliters (mL); V3-total volume of sample solution, in milliliters (mL); m-mass of sample, in grams (g); V2-volume of digestion solution for preparing sample solution, in milliliters (mL); V4-volume of sample solution for determination, in milliliters (mL); 1000-conversion factor; 100-total volume of digestion solution, in milliliters (mL); F-coefficient of nitrogen conversion to protein.
[0126] The calculated pearl protein peptide yields and preparation costs (amount of enzyme used × commercial unit price) of different proteases are shown in the following table.
[0127] Table 3 Pearl protein peptide yield and preparation cost of different proteases
[0128] Protease Type Extraction rate (%) Extraction cost (yuan / kg) Alkaline protease 84.3±2.3 11300 Acid protease 17.2±5.6 58388 Neutral protease 26.2±0.8 46352 Trypsin 22.1±3.3 63100 Bromelain 42.7±5.1 42311 Papain 40.1±1.6 33765 Flavor protease 38.2±0.6 24947
[0129] The above results show that the extraction rate of pearl protein peptides by the alkaline protease in the present application is significantly higher than that of other types of proteases by 41.6%-67.1%, and the extraction cost is reduced by about 54.7%-82.1%.
[0130] The inventors measured the extraction rates of other alkaline protease mutants obtained by the same preparation method and measurement method as the above examples, and found that the above 8 mutants can achieve the extraction effect of BG1. The extraction rates of some mutants are shown in the following table.
[0131] Table 4 Pearl protein peptide yields of alkaline protease mutants
[0132] Protease Type Extraction rate (%) Alkaline proteinase BG1 84.3±2.3 Alkaline protease mutant BG1-S47L 77.6±1.7 Alkaline protease mutant BG1-V57I 83.1±2.0 Alkaline protease mutant BG1-Q115L 86.2±1.2 Alkaline protease mutant BG1-I136L 85.9±0.6 Alkaline protease mutant BG1-S182A 94.1±2.2 Alkaline protease mutant BG1-L239M 87.0±1.4 Alkaline protease mutant BG1-T262A 88.9±1.5
[0133] The above results indicate that the alkaline protease mutants in the present application can achieve a pearl protein peptide yield that is much higher than the extraction rate of other types of proteases.
[0134] Example 3
[0135] In this example, the molecular weight distribution of the pearl protein peptides obtained by enzymatic hydrolysis with different proteases obtained in Example 2 was detected. The specific detection method is as follows:
[0136] In this embodiment, water (purified water, Milli-Q water or similar grade) is used as a diluent, and relative molecular mass standard substances are used as reference substances to perform chromatographic analysis on pearl protein peptides hydrolyzed by different proteases. Among them, the relative molecular mass standard substances include: cytochrome C-12384 (reagent grade or similar grade); aprotinin-6511.44 (reagent grade or similar grade); bacitracin-1422.69 (reagent grade or similar grade); papain inhibitor-451.48 (reagent grade or similar grade); dianhydride aminoacyl glycine-189.17 (reagent grade or similar grade). Among them, water is used as a blank solution, and about 25.0 mg of the reference substance is taken respectively, placed in the same 25 mL volumetric flask, and the diluent (water) is added to shake and dissolve and dilute to the scale, and shake well (about 1.0 mg / mL). Pearl protein peptides hydrolyzed by different proteases are used as test samples, and are directly sampled after centrifugal filtration.
[0137] The chromatographic conditions are:
[0138] Chromatograph: Agilent 1260 or similar liquid chromatograph; Chromatographic column: Tskgel G2000SW, 30cm×7.8mm or similar column; Mobile phase: acetonitrile-purified water-trifluoroacetic acid (40:60:0.05) (v / v / v), accurately measure 400mL acetonitrile (HPLC or similar grade) and 600mL purified water, pipette 0.5mL trifluoroacetic acid (AR grade or similar grade), stir evenly, and degas by ultrasonic. Column temperature: 30℃; Flow rate: 0.5mL / min; Sample chamber temperature: room temperature; Injection volume: 10μL; Detector wavelength: UV220nm; Run time: isocratic run for 30min; Needle washing reagent: acetonitrile-purified water-trifluoroacetic acid (40:60:0.05) (v / v / v); Data acquisition: Computer with OpenLAB CDS or similar software installed.
[0139] The measurement process is as follows: inject one injection of the test solution, record the chromatogram, and then continue to inject other batches of test solution.
[0140] The retention times are shown in the table below.
[0141] Table 5 Retention time of relative molecular mass standard substances
[0142] Substance name Retention time / RT(min) Cytochrome C Approx. 11.2 Aprotinin About 12.4 Bacitracin Approx. 14.5 Papain inhibitors Approx. 16.2 Dianhydramidine About 18.6
[0143] The injection sequence is shown in the table below.
[0144] Table 6 Injection sequence
[0145] Solution name share stitches blank solution 1 1 needle or more needles Identification sample solution 1 1 Test solution 1 1 1 Test solution 2 1 1 … 1 1
[0146] The detection has been seen in Table 7-8 and Figure 1-3 shown.
[0147] Table 7 Detection accuracy of reference products
[0148]
[0149] Table 8 Protein content of enzymatic hydrolysates of different enzymes
[0150] Protease Type Small molecule peptides (0.1-13kDa) content ratio Alkaline protease (BG1) 93% Acid protease 2.6% Neutral protease 13% Trypsin 11.6% Bromelain 59.5% Papain 8% Flavor protease 38%
[0151] The above results show that the detection results in this embodiment are accurate. The small molecule protein of the pearl protein peptide product extracted by alkaline protease in the embodiment of the present invention accounts for about 93%, which is more than 30% higher than other proteases, making it easier to be absorbed and utilized by the human body.
[0152] The pearl protein peptide products prepared by using other mutants prepared in the examples of the present invention were tested under the same conditions, and it was found that the proportion of small molecule proteins in the pearl protein peptide products prepared by using other mutants prepared in the examples of the present invention was similar to that of BG1, among which some mutants (such as BG1-Q115L, BG1-I136L, BG1-S182A, BG1-L239M and BG1-T262A) were even slightly better than BG1.
[0153] Example 4
[0154] In this example, the pearl protein peptides obtained by enzymatic hydrolysis with different proteases obtained in Example 2 were tested for their tyrosinase activity inhibition performance to determine the whitening efficacy of these pearl protein peptides.
[0155] Among them, the basic principle of the whitening effect determination based on tyrosinase is that tyrosinase is the rate-limiting enzyme in the melanin synthesis pathway, which mainly affects the production of melanin by affecting the conversion of tyrosine into dopa and the oxidation of dopa into dopaquinone. Therefore, the whitening effect of the whitening agent can be evaluated by measuring the inhibition of tyrosinase on tyrosinase.
[0156] The specific detection methods are as follows:
[0157] The pearl protein peptides obtained in the above examples using different protease hydrolysis were added to distilled water respectively, the ratio of pearl protein peptide to water was 50 mg / mL, and the pearl protein peptide aqueous solution was obtained after mixing. Methyl parahydroxybenzoate was added to butanediol, the ratio of methyl parahydroxybenzoate to butanediol was 0.2 g: 100 mL, and after ultrasonic mixing, a butanediol-methyl parahydroxybenzoate solution was obtained. The pearl protein peptide aqueous solution and the butanediol-methyl parahydroxybenzoate solution were mixed together in a ratio of 1: 1 (volume ratio) to obtain a composite pearl protein peptide crude solution. The composite pearl protein peptide crude solution was centrifuged at a speed of 8000 rpm for 10 minutes to remove the precipitate, and a composite pearl protein peptide solution with a final concentration of 40 mg / mL of pearl protein peptide was obtained.
[0158] In a 96-well ELISA plate, set up solvent background wells (Ta), solvent reaction wells (Tb), sample background wells (Tc), and sample reaction wells (Td). Among them, the Ta group is a solvent background group, without adding substrate L-tyrosine solution and sample solution; the Tb group is a solvent reaction group, with substrate L-tyrosine solution but no sample solution; the Tc group is a sample background group, without adding substrate L-tyrosine solution and adding sample solution; the Td group is a sample reaction group, with both substrate L-tyrosine solution and sample solution. Three replicate wells are made for each group. The specific sample addition conditions of each group are shown in Table 9.
[0159] The preparation method of L-tyrosine solution is as follows: weigh 0.025 g of L-tyrosine, dissolve it with PBS buffer, dissolve it with ultrasonic aid, make the volume to 50 mL, and use it immediately after preparation.
[0160] Table 9 Sample addition table for tyrosinase activity inhibition test
[0161]
[0162] The tyrosinase solution is prepared by using PBS buffer to prepare mushroom tyrosinase (CAS No.: 9002-10-2) to a concentration of 500 U / mL.
[0163] According to the reagent addition amount in Table 9, PBS buffer, L-tyrosine solution, sample solution, and solvent were added to each well in sequence, mixed thoroughly, and incubated at 37°C for 10 minutes. Then, 20 μL of tyrosinase solution was added to each well in sequence, and mixed and reacted at 37°C for 5 minutes ± 5 seconds. After the reaction was completed, the well was immediately placed in the microplate reader and the absorbance was measured at a wavelength of 475 nm.
[0164] The inhibition rate of each sample on tyrosinase was calculated according to the following formula, and the results were expressed as mean ± standard deviation (x + SD).
[0165]
[0166] Where:
[0167] Y-tyrosinase activity inhibition rate; Ad-sample reaction well absorbance; Ac-sample background well absorbance; Ab-average absorbance of solvent reaction well; Aa-average absorbance of solvent background well.
[0168] When the results are counted and analyzed, the standard deviation (SD) of the inhibition rate between the parallel wells of each group must be ≤15% to consider the parallelism of the test valid. The tyrosinase inhibition rate of the sample at a certain test concentration should be expressed as: the mean inhibition rate ± the standard deviation (SD) between the inhibition rates. The tyrosinase inhibition ability of different samples is compared. At the same test concentration, the greater the inhibition rate, the stronger the tyrosinase inhibition ability of the sample.
[0169] In this example, some experimental results are exemplified (as shown in the following table, other alkaline proteases in the examples of the present invention are basically similar to BG1-S182A).
[0170] Table 10 Test results of pearl protein peptide tyrosinase activity inhibition performance of different proteases
[0171] Group Tyrosinase activity inhibition rate (%) Alkaline protease mutant BG1-S182A 100±3.5 Acid protease 86.6±7.2 Neutral protease 81.5±5.1 Trypsin 86.8±3.5 Bromelain 75.4±5.7 Papain 99.6±0.1 Flavor protease 87.9±3.3
[0172] The above results show that the tyrosinase activity inhibition rate of the pearl protein peptide obtained by enzymatic hydrolysis of the alkaline protease (BG1 and its mutants) in the embodiment of the present invention is significantly higher than the enzymatic hydrolysis effect of other types of proteases after compounding. The active protein peptide can be used as a cosmetic raw material to enhance the whitening effect of cosmetics by 0.4%-25.6%.
[0173] Example 4
[0174] In this example, the antioxidant capacity of the pearl protein peptides obtained by hydrolysis with different proteases in Example 2 was tested.
[0175] The antioxidant capacity is tested by the ABTS method. The basic principle is that ABTS will be oxidized into green ABTS+ under the action of appropriate oxidants. When antioxidants are present, the production of ABTS+ will be inhibited. The total antioxidant capacity of the sample can be measured and calculated by measuring the absorbance of ABTS+ at 734nm or 405nm. Trolox is a vitamin E analog with antioxidant capacity similar to vitamin E and is used as a reference for the total antioxidant capacity of other antioxidants.
[0176] Use PBS to dilute the 10mM Trolox standard solution to 0.15, 0.3, 0.6, and 0.9mM respectively. Add 10μL of the above diluted Trolox standard solution of different concentrations to the 96-well plate, add PBS to the blank control well, and then add 200μL of ABTS working solution to each well, shake in the microplate reader for 5 seconds to mix, incubate at room temperature for 5 minutes, measure the absorbance A734nm, and plot the results as a regression curve between absorbance value and concentration. The preparation method of ABTS working solution is: according to the number of samples to be tested, use equal volumes of ABTS solution and oxidant solution to prepare ABTS working stock solution, and store it at room temperature away from light for 12-16 hours after preparation before use. Before use, dilute the ABTS working solution with PBS to make ABTS working solution. The absorbance of the ABTS working solution minus the corresponding PBS blank control should be 0.7±0.005 at 734nm and about 1.4 at 405nm (the diluted ABTS working solution should be used within half an hour).
[0177] In this embodiment, the standard curve is:
[0178]
[0179] Linear range: 0.15~0.9mmol / L Trolox.
[0180] It should be noted that after replacing the reagents, the calibration curve needs to be re-performed to ensure the validity of the data.
[0181] The sample to be tested needs to be diluted 8 times with PBS (so that the absorbance is within the standard curve range and remains stable within the reaction time of 2-6 minutes). The diluted sample solvent is used as a blank control. Add 10μL of the above diluted blank control and the sample to be tested to the 96-well plate, and then add 200μL of ABTS working solution to each well, shake in the microplate reader for 5 seconds to mix, incubate at room temperature for 5 minutes, and measure the absorbance (734nm), and measure three times for each group. Substitute the results into the standard curve and multiply back the corresponding dilution factor to calculate the total antioxidant capacity of the sample.
[0182] When using Trolox as a standard to measure the total antioxidant capacity, the antioxidant capacity of the sample can be directly expressed by the molar concentration of Trolox. For example, if the inhibition rate of a sample is the same as that of 0.6mM Trolox, the total antioxidant capacity of the sample is 0.6mM; if the inhibition rate of a sample diluted 5 times is the same as that of 0.5mM Trolox, the total antioxidant capacity of the sample is 2.5mM.
[0183] In this example, some experimental results are exemplified (as shown in the following table, other alkaline proteases in the examples of the present invention are basically similar to BG1-S182A).
[0184] Table 11 Test results of the antioxidant capacity of pearl protein peptides with different proteases
[0185] Group ABTS antioxidant capacity (mM) Alkaline protease mutant BG1-S182A 4.76±0.05 Acid protease 0.33±0.07 Neutral protease 1.79±0.06 Trypsin 1.15±0.07 Bromelain 3.06±0.05 Papain 4.05±0.02 Flavor protease 4.23±0.03
[0186] The above results show that the antioxidant capacity of ABTS obtained by enzymatic hydrolysis of the pearl protein peptides obtained by alkaline protease (BG1 and its mutants) in the examples of the present invention is significantly higher than the enzymatic hydrolysis effect of other types of proteases after compounding. The active protein peptide can be used as a cosmetic raw material to enhance the antioxidant effect of cosmetics by 11.2%-93.1%.
[0187] Example 5
[0188] In this example, the pearl protein peptides obtained by hydrolysis with different proteases in Example 2 were tested for their moisturizing ability.
[0189] Among them, the moisturizing ability is characterized by the hygroscopicity and moisturizing properties of the substance. The basic principle is that the function of the moisturizer in cosmetics is to maintain or increase the water content of the stratum corneum, improve or repair the clinical symptoms such as dry skin, itching and desquamation caused by lack of water in the stratum corneum. Therefore, by testing the hygroscopicity and moisturizing properties of pearl protein peptides, a reference can be made for the moisturizing ability of the active peptides in cosmetics of the present invention.
[0190] The specific experimental steps are as follows:
[0191] Add saturated sodium carbonate and saturated ammonium sulfate solutions to a clean desiccator respectively, and apply a layer of vaseline cream on the cover of the desiccator to seal the desiccator. Take another desiccator and put two bottles of dry silica gel particles in it. Seal the three desiccators for 4 hours. Put a hygrometer in each of the three desiccators, observe the humidity change every hour, and keep it for use after the humidity reaches stability. Put the pearl protein peptide dry powder prepared in the above embodiment into a 30°C oven and dry it to a constant weight state. Weigh 0.5g of the dried pearl protein peptide dry powder, add it to the three desiccators respectively, and then add 10% water by mass. Weigh and record every 4 hours. Among them, the preparation method of saturated sodium carbonate and saturated ammonium sulfate is: add excess sodium carbonate or ammonium sulfate to a 1L glass bottle, dissolve it by ultrasonication, and obtain a saturated sodium carbonate solution or a saturated ammonium sulfate solution when the sodium carbonate or ammonium sulfate is not completely dissolved.
[0192] In this example, some experimental results are exemplified (as shown in the following table, other alkaline proteases in the examples of the present invention are basically similar to BG1-S182A).
[0193] Table 12 Test results of the antioxidant capacity of pearl protein peptides with different proteases
[0194] Group 24h moisture absorption rate (%) 24h Moisturizing Rate (%) Alkaline protease mutant BG1-S182A 41.4±2.3 25.8±2.8 Acid protease 35±3.1 13.1±2.6 Neutral protease 22.8±1.1 11.1±4.5 Trypsin 25.6±2.5 17.5±3.1 Bromelain 40.1±2.3 22.8±2.6 Papain 35.4±3.2 6.4±1.7 Flavor protease 27±2.9 11±2.4
[0195] The above results show that the moisturizing ability of the pearl protein peptide obtained by enzymatic hydrolysis of the alkaline protease (BG1 and its mutants) in the embodiment of the present invention is significantly higher than the enzymatic hydrolysis effect of other types of proteases after compounding. The active protein peptide can be used as a cosmetic raw material to improve the moisturizing effect of cosmetics by 3%-19.4%.
[0196] Example 6
[0197] This embodiment provides a method for preparing pearl protein peptide, comprising the following steps:
[0198] (1) Pearl powder and purified water are mixed to obtain a pearl powder water suspension, wherein the ratio of pearl powder to purified water is 1 g: 6 mL. Subsequently, protease is added to the pearl powder water suspension at a ratio of 0.02 g of protease per 1 g of pearl powder, and enzymolysis is performed at 55° C. for 4 hours to obtain an enzymolysis solution.
[0199] (2) The temperature of the enzymatic hydrolyzate obtained in step (1) was raised to 95° C., and the enzyme was inactivated for 20 min.
[0200] (3) The enzymatic hydrolysate after the enzyme inactivation in step (2) is cooled to room temperature, and then centrifuged at 8000 rpm in a high-speed centrifuge to remove the precipitate and obtain the enzymatic hydrolysate supernatant.
[0201] (4) Using a 90 mm glass funnel and double-layer medium-speed filter paper, filter the supernatant of the enzymatic hydrolyzate obtained in step (3) twice to remove impurities.
[0202] (5) The enzymatic hydrolysate filtered in step (4) is concentrated by rotary evaporation at 65° C., wherein the volume of the enzymatic hydrolysate after concentration is 1 / 10 of that before concentration.
[0203] (6) freeze-drying the concentrated enzymatic hydrolysate obtained in step (5) using a freeze dryer to obtain pearl protein peptide dry powder. The freeze-drying treatment conditions at least meet at least one of the following: the vacuum degree of the freeze-drying treatment is 1 Pa, the temperature is -80°C, and the time is 120 hours.
[0204] The difference between the preparation method of this embodiment and that of embodiment 2 is that the material-liquid ratio of pearl powder and purified water is reduced from 1:10 to 1:6.
[0205] Example 7
[0206] This embodiment provides a method for preparing pearl protein peptide, comprising the following steps:
[0207] (1) Pearl powder and purified water are mixed to obtain a pearl powder water suspension, wherein the ratio of pearl powder to purified water is 1 g:10 mL. Subsequently, protease is added to the pearl powder water suspension at a ratio of 0.02 g of protease per 1 g of pearl powder, and enzymolysis is performed at 55° C. for 8 hours to obtain an enzymolysis solution.
[0208] (2) The temperature of the enzymatic hydrolyzate obtained in step (1) was raised to 95° C., and the enzyme was inactivated for 20 min.
[0209] (3) The enzymatic hydrolysate after the enzyme inactivation in step (2) is cooled to room temperature, and then centrifuged at 8000 rpm in a high-speed centrifuge to remove the precipitate and obtain the enzymatic hydrolysate supernatant.
[0210] (4) Using a 90 mm glass funnel and double-layer medium-speed filter paper, filter the supernatant of the enzymatic hydrolyzate obtained in step (3) twice to remove impurities.
[0211] (5) The enzymatic hydrolysate filtered in step (4) is concentrated by rotary evaporation at 65° C., wherein the volume of the enzymatic hydrolysate after concentration is 1 / 10 of that before concentration.
[0212] (6) freeze-drying the concentrated enzymatic hydrolysate obtained in step (5) using a freeze dryer to obtain pearl protein peptide dry powder. The freeze-drying treatment conditions at least meet at least one of the following: the vacuum degree of the freeze-drying treatment is 1 Pa, the temperature is -80°C, and the time is 120 hours.
[0213] The difference between the preparation method of this embodiment and that of embodiment 2 is that the enzymatic hydrolysis time is increased from 4 h to 8 h.
[0214] Example 8
[0215] This embodiment provides a method for preparing pearl protein peptide, comprising the following steps:
[0216] (1) The pearl powder is sieved (80 mesh sieve) and sorted, and the pearl powder with a particle size greater than 80 mesh is mixed with purified water to obtain a pearl powder water suspension, wherein the ratio of pearl powder to purified water is 1 g:10 mL. Subsequently, protease is added to the pearl powder water suspension at a ratio of 0.02 g of protease per 1 g of pearl powder, and enzymolysis is performed at 55° C. for 4 hours to obtain an enzymolysis solution.
[0217] (2) The temperature of the enzymatic hydrolyzate obtained in step (1) was raised to 95° C., and the enzyme was inactivated for 20 min.
[0218] (3) The enzymatic hydrolysate after the enzyme inactivation in step (2) is cooled to room temperature, and then centrifuged at 8000 rpm in a high-speed centrifuge to remove the precipitate and obtain the enzymatic hydrolysate supernatant.
[0219] (4) Using a 90 mm glass funnel and double-layer medium-speed filter paper, filter the supernatant of the enzymatic hydrolyzate obtained in step (3) twice to remove impurities.
[0220] (5) The enzymatic hydrolysate filtered in step (4) is concentrated by rotary evaporation at 65° C., wherein the volume of the enzymatic hydrolysate after concentration is 1 / 10 of that before concentration.
[0221] (6) freeze-drying the concentrated enzymatic hydrolysate obtained in step (5) using a freeze dryer to obtain pearl protein peptide dry powder. The freeze-drying treatment conditions at least meet at least one of the following: the vacuum degree of the freeze-drying treatment is 1 Pa, the temperature is -80°C, and the time is 120 hours.
[0222] The difference between the preparation method of this embodiment and that of embodiment 2 is that the mixed pearl powders with different particle sizes are replaced with pearl powders with a particle size greater than 80 meshes.
[0223] Example 9
[0224] In this example, the inventors compared the pearl protein peptide preparation method in Example 2 of the present invention with the conventional method in the prior art. The specific comparison is shown in the following table.
[0225] Table 13 Comparison of the effects of different pearl protein peptide preparation methods
[0226]
[0227] Among them, ultrasound-assisted extraction, microwave-assisted extraction, acid hydrolysis and water extraction all adopt the methods used in the existing technology (Pei, Jingying, et al. "Extraction, Purification, Bioactivities and Application of Matrix Proteins From Pearl Powder and Nacre Powder: A Review." Frontiers in bioengineering and biotechnology, DOI: 10.3389 / fbioe.2021.649665).
[0228] In summary, the method of preparing pearl protein peptides by enzymatic hydrolysis of an aqueous suspension containing pearl powder using alkaline protease or its mutant obtained in the embodiment of the present invention has a short reaction time and a high extraction rate; and the separation and purification method of the method is simple, which greatly reduces the high cost of traditional extraction; it is safe and environmentally friendly, and is very conducive to industrial production. In addition, the pearl protein peptides obtained by enzymatic hydrolysis of alkaline protease or its mutant obtained in the embodiment of the present invention have stronger whitening activity, antioxidant function and moisturizing effect after compounding. The pearl protein peptides after compounding have the advantages of being conducive to skin absorption and good permeability, and can be widely used in the preparation process of cosmetics, further promoting the efficient application of pearl powder.
[0229] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.
Claims
1. An alkaline protease or a mutant thereof, It is characterized in that The alkaline protease contains the amino acid sequence shown in SEQ ID NO: 1; the alkaline protease mutant has an amino acid sequence with at least 95% sequence identity with the amino acid sequence shown in SEQ ID NO: 1, and the alkaline protease mutant retains protein hydrolysis catalytic activity.
2. The alkaline protease or a mutant thereof according to claim 1, It is characterized in that The alkaline protease mutant has an amino acid sequence having at least 97% sequence identity with the amino acid sequence shown in SEQ ID NO: 1; Preferably, the alkaline protease mutant is an alkaline protease mutant obtained by replacing, adding or deleting at least one amino acid of the alkaline protease; Preferably, the alkaline protease mutant is an alkaline protease mutant obtained by replacing, adding or deleting 1 to 8 amino acids of the alkaline protease.
3. The alkaline protease or a mutant thereof according to claim 1 or 2, It is characterized in that The alkaline protease mutant is an alkaline protease mutant obtained by amino acid substitution at at least one amino acid residue among 47S, 57V, 115Q, 136I, 182S, 239L, 262T or 244S of the alkaline protease; Preferably, the alkaline protease mutant comprises an amino acid sequence as shown in SEQ ID NO: 3, 5, 7, 9 or 11.
4. A biological product, It is characterized in that The biological products include: (1) A nucleic acid molecule encoding the alkaline protease or a mutant thereof according to any one of claims 1 to 3; (2) an expression vector containing the nucleic acid molecule described in (1); (3) A transformant containing the nucleic acid molecule described in (1); (4) a transformant containing the expression vector described in (2); Wherein, the transformants do not involve animal or plant propagation materials; Preferably, the expression vector includes virus, plasmid and bacteriophage; Preferably, the transformants include bacteria, fungi, animals and plants.
5. Use of the alkaline protease or its mutant according to any one of claims 1 to 3, or the biological product according to claim 4 in enzyme engineering; Preferably, the enzyme engineering comprises enzymatic hydrolysis of pearl protein peptides.
6. A method for preparing pearl protein peptide, comprising the following steps: Add alkaline protease to the solution containing pearl powder, and perform enzymolysis at 40-65°C for 2-10h to obtain the product; in, The alkaline protease comprises the alkaline protease or a mutant thereof according to any one of claims 1 to 3; Preferably, the mass ratio of the pearl powder to the protease is 1:0.001-0.04; Preferably, the material-liquid ratio of the pearl powder to the solvent is 1:5-10; Preferably, no pH adjustment is performed in the process.
7. The preparation method according to claim 6, It is characterized in that The method further comprises: purifying and / or enriching the enzymatic hydrolysis product after enzymatic hydrolysis; Preferably, the purification and / or enrichment comprises centrifuging, filtering and / or evaporating and concentrating the enzymatic hydrolysis product; and / or The method further comprises performing an enzyme inactivation treatment after the enzymatic hydrolysis; Preferably, the enzyme inactivation treatment comprises at least one of increasing temperature, adding enzyme inhibitors, increasing pressure or applying voltage.
8. Pearl protein peptide prepared by the preparation method according to any one of claims 6 to 7, It is characterized in that The content of small molecule peptides in the pearl protein peptide is greater than or equal to 60%, preferably greater than or equal to 80%; more preferably greater than or equal to 90%; Wherein, the small molecule peptide is a peptide less than or equal to 13 kDa.
9. A daily necessity, It is characterized in that The daily necessities contain the pearl protein peptide described in claim 8.
10. Use of the pearl protein peptide described in claim 8 in the preparation of medicines or cosmetics; Preferably, the medicine or cosmetic has at least one of the following functions: (1) Antioxidant or anti-aging; (2) Whitening and darkening; (3) Store water and keep moisturized.
